Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Monte Rosa Therapeutics is a clinical-stage biotechnology company pioneering molecular glue degrader (MGD) therapeutics, a novel protein degradation approach targeting previously undruggable proteins. The company's lead asset MRT-2359 is in Phase 1/2 trials for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma, targeting GSPT1 degradation. With $1.2B market cap and minimal revenue ($0.1B), the stock trades on clinical milestone expectations and platform validation rather than commercial fundamentals.
Monte Rosa operates a pre-commercial R&D model focused on discovering and developing molecular glue degraders that induce targeted protein degradation. The company monetizes its proprietary QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery platform through strategic partnerships while advancing wholly-owned oncology programs. Revenue currently derives from upfront payments and research funding from collaborators, with future economics dependent on achieving clinical milestones, regulatory approvals, and eventual commercialization. The 89.3% gross margin reflects the high-margin nature of collaboration revenue versus minimal COGS. Pricing power will emerge only upon successful clinical validation and FDA approval, typical 2028-2030 timeframe for lead assets.
MRT-2359 Phase 1/2 clinical trial data readouts in multiple myeloma and DLBCL (safety, efficacy, response rates)
Advancement of pipeline candidates (MRT-6160 for solid tumors, NEK7 degrader programs) into clinical trials
Strategic partnership announcements or expansion of existing collaborations (Roche, Novartis partnerships)
FDA regulatory interactions, IND clearances, or breakthrough therapy designations
Competitive developments in protein degradation space (PROTACs, molecular glues from Arvinas, C4 Therapeutics, Nurix)
Cash runway updates and financing activities (equity raises, debt facilities)
Clinical trial failure risk: MRT-2359 or pipeline candidates may fail to demonstrate sufficient efficacy or acceptable safety profiles in ongoing or future trials, resulting in program termination and significant value destruction
Regulatory approval uncertainty: Novel molecular glue mechanism lacks established precedent with FDA, potentially creating longer review timelines or additional clinical requirements versus traditional small molecules
Competitive technology displacement: PROTAC degraders, other molecular glue approaches, or alternative modalities (ADCs, bispecifics) may prove superior, commoditizing Monte Rosa's platform advantage
Reimbursement risk: Even with approval, payer willingness to cover novel degrader therapies at premium pricing remains unproven, particularly in crowded oncology indications
Established protein degradation competitors (Arvinas, Kymera, C4 Therapeutics) with more advanced clinical programs and greater resources may capture partnership opportunities and validate competing platforms first
Large pharma internal degrader programs (Roche, Novartis, BMS) could reduce demand for external partnerships or create well-funded competitive assets
Target competition: Multiple companies pursuing GSPT1 degradation in hematologic malignancies creates risk of clinical trial enrollment challenges and eventual market share fragmentation
Cash runway risk: With near-zero operating cash flow and high burn rate, the company will require additional financing within 12-24 months; dilutive equity raises or unfavorable partnership terms could result if capital markets deteriorate
Partnership dependency: Minimal internal revenue generation creates reliance on collaboration payments for non-dilutive funding; loss of key partnerships (Roche, Novartis) would accelerate cash burn and force equity financing
low - Pre-revenue biotech with no commercial exposure to consumer spending or GDP fluctuations. Clinical trial timelines and regulatory processes are largely insulated from economic cycles. However, severe recessions can impact: (1) ability to raise capital at favorable valuations, (2) partnership deal flow as pharma companies tighten budgets, (3) patient enrollment if healthcare utilization declines.
Rising interest rates create significant valuation pressure on pre-revenue biotechs through two mechanisms: (1) higher discount rates applied to distant future cash flows (potential product revenues 4-8 years out), compressing NPV of pipeline assets, (2) increased competition from risk-free Treasury yields making speculative biotech investments less attractive on a risk-adjusted basis. The 6.54 current ratio and minimal debt (0.16 D/E) provide cushion against financing cost increases, but equity financing becomes more dilutive in high-rate environments. The 302.6% six-month return suggests recent rate stabilization or cuts have benefited valuation multiples.
Minimal direct credit exposure given negligible debt levels (0.16 D/E ratio) and strong liquidity (6.54 current ratio). However, tightening credit conditions indirectly impact biotech sector through: (1) reduced M&A activity from cash-constrained acquirers, (2) more difficult venture debt access for runway extension, (3) wider high-yield spreads increasing cost of convertible debt financing. The company's ability to access capital markets for future funding rounds is more sensitive to equity market sentiment than credit conditions.
growth - Pure clinical-stage speculation attracting biotech-focused growth investors, venture capital crossover funds, and momentum traders. The 180.3% one-year return and 302.6% six-month surge indicate strong momentum participation. No dividend income, negative earnings preclude value investors. High-risk/high-reward profile typical of Phase 1/2 oncology assets where binary clinical outcomes drive 50%+ single-day moves. Institutional ownership likely concentrated among specialized healthcare funds (Perceptive, RA Capital, Boxer) rather than broad index funds.
high - Clinical-stage biotech with binary event risk exhibits extreme volatility around data readouts, regulatory decisions, and financing events. The 302.6% six-month return demonstrates explosive upside potential, but comparable downside risk exists on negative clinical data. Estimated beta >1.5 versus biotech indices, with 30-50% intraday swings possible on trial results. Low float and institutional concentration amplify volatility. Options market likely prices elevated implied volatility (>80%) around known catalyst dates.
